Tags

Type your tag names separated by a space and hit enter

Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
Thromb Res. 2008; 122(1):39-45.TR

Abstract

The aim of this study was to determine whether pitavastatin may prevent the progression of atherosclerotic changes in hyperlipidemic patients. Seventy-five hyperlipidemic patients with and without type 2 diabetes were enrolled to receive pitavastatin 2 mg daily. Cell adhesion molecules (sCD40L, sP-selectin, sE-selectin, and sL-selectin), chemokines (MCP-1 and RANTES) and adiponectin were measured at baseline and after 3 and 6 months of pitavastatin treatment. Adiponectin levels prior to pitavastatin treatment in hyperlipidemic patients with and without diabetes were lower than levels in normolipidemic controls. Both total cholesterol and the LDL-cholesterol (LDL-C) decreased significantly after pitavastatin administration. Additionally, hyperlipidemic patients with type 2 diabetes exhibited a significant increase in adiponectin levels after pitavastatin treatment (before vs. 3 months, 6 months, 2.81+/-0.95 vs. 3.84+/-0.84 microg/ml (p<0.01), 4.61+/-1.15 mug/ml (p<0.001)). Furthermore, hyperlipidemic diabetics exhibited significant decreases in sE-selectin and sL-selectin levels after 6 months of pitavastatin treatment (sE-selectin, before vs. 6 months, 74+/-21 vs. 51+/-10 ng/ml, p<0.05; sL-selectin, before vs. 6 months, 896+/-141 vs. 814+/-129 ng/ml, p<0.05). In addition, adiponectin showed significant correlation with sE-selectin and sL-selectin in diabetic hyperlipidemia. However, MCP-1, RANTES and sCD40L did not exhibit any differences before or after pitavastatin administration. These results suggest that pitavastatin possesses an adiponectin-dependent anti-atherosclerotic effect in hyperlipidemic patients with type 2 diabetes in addition to its lowering effects on total cholesterol and LDL-C.

Authors+Show Affiliations

Division of Hematology, Kishiwada City Hospital, 1001 Gakuhara-cho, Kishiwada, Osaka 596-8501, Japan. shosaku-n@mbp.ocn.ne.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17920663

Citation

Nomura, Shosaku, et al. "Correlation Between Adiponectin and Reduction of Cell Adhesion Molecules After Pitavastatin Treatment in Hyperlipidemic Patients With Type 2 Diabetes Mellitus." Thrombosis Research, vol. 122, no. 1, 2008, pp. 39-45.
Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39-45.
Nomura, S., Shouzu, A., Omoto, S., Inami, N., Tanaka, A., Nanba, M., Shouda, Y., Takahashi, N., Kimura, Y., & Iwasaka, T. (2008). Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thrombosis Research, 122(1), 39-45.
Nomura S, et al. Correlation Between Adiponectin and Reduction of Cell Adhesion Molecules After Pitavastatin Treatment in Hyperlipidemic Patients With Type 2 Diabetes Mellitus. Thromb Res. 2008;122(1):39-45. PubMed PMID: 17920663.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. AU - Nomura,Shosaku, AU - Shouzu,Akira, AU - Omoto,Seitarou, AU - Inami,Norihito, AU - Tanaka,Atsushi, AU - Nanba,Masashi, AU - Shouda,Yoshihiro, AU - Takahashi,Nobuyuki, AU - Kimura,Yutaka, AU - Iwasaka,Toshiji, Y1 - 2007/10/17/ PY - 2007/03/03/received PY - 2007/08/04/revised PY - 2007/08/20/accepted PY - 2007/10/9/pubmed PY - 2008/8/12/medline PY - 2007/10/9/entrez SP - 39 EP - 45 JF - Thrombosis research JO - Thromb. Res. VL - 122 IS - 1 N2 - The aim of this study was to determine whether pitavastatin may prevent the progression of atherosclerotic changes in hyperlipidemic patients. Seventy-five hyperlipidemic patients with and without type 2 diabetes were enrolled to receive pitavastatin 2 mg daily. Cell adhesion molecules (sCD40L, sP-selectin, sE-selectin, and sL-selectin), chemokines (MCP-1 and RANTES) and adiponectin were measured at baseline and after 3 and 6 months of pitavastatin treatment. Adiponectin levels prior to pitavastatin treatment in hyperlipidemic patients with and without diabetes were lower than levels in normolipidemic controls. Both total cholesterol and the LDL-cholesterol (LDL-C) decreased significantly after pitavastatin administration. Additionally, hyperlipidemic patients with type 2 diabetes exhibited a significant increase in adiponectin levels after pitavastatin treatment (before vs. 3 months, 6 months, 2.81+/-0.95 vs. 3.84+/-0.84 microg/ml (p<0.01), 4.61+/-1.15 mug/ml (p<0.001)). Furthermore, hyperlipidemic diabetics exhibited significant decreases in sE-selectin and sL-selectin levels after 6 months of pitavastatin treatment (sE-selectin, before vs. 6 months, 74+/-21 vs. 51+/-10 ng/ml, p<0.05; sL-selectin, before vs. 6 months, 896+/-141 vs. 814+/-129 ng/ml, p<0.05). In addition, adiponectin showed significant correlation with sE-selectin and sL-selectin in diabetic hyperlipidemia. However, MCP-1, RANTES and sCD40L did not exhibit any differences before or after pitavastatin administration. These results suggest that pitavastatin possesses an adiponectin-dependent anti-atherosclerotic effect in hyperlipidemic patients with type 2 diabetes in addition to its lowering effects on total cholesterol and LDL-C. SN - 0049-3848 UR - https://www.unboundmedicine.com/medline/citation/17920663/Correlation_between_adiponectin_and_reduction_of_cell_adhesion_molecules_after_pitavastatin_treatment_in_hyperlipidemic_patients_with_type_2_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0049-3848(07)00331-3 DB - PRIME DP - Unbound Medicine ER -